Market revenue in 2023 | USD 21.6 million |
Market revenue in 2030 | USD 55.0 million |
Growth rate | 14.3% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.91% in 2023. Horizon Databook has segmented the South Africa hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
South Africa's hereditary angioedema therapeutics market is expected to witness lucrative growth over the forecast period, owing to the increasing prevalence of HAE, supportive government initiatives, and increased demand for effective therapeutics.
According to a review article published by the Division of Allergology and Clinical Immunology, the estimated prevalence of HAE in the country is 1 per 150,000 cases, close to 400 cases of HAE. Several initiatives enabling better and affordable access to treatment are being taken in the country.
For instance, in February 2023, Sinovuyo South African Virtual Angioedema Centre, a newly established medical help platform, was launched at UCT to provide affordable access to HAE treatment nationwide.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into South Africa hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account